FY27 Outlook Improves for Indian Markets with Better Macros and Earnings Revival: Manish Sonthalia
Manish Sonthalia from Emkay Investment Managers predicts a positive outlook for Indian markets in FY27, expecting 12-13% earnings growth driven by low inflation and reduced interest rates. He anticipates strong performance in sectors like banks, IT, capital goods, NBFCs, and healthcare. Rate-sensitive sectors such as real estate and automobiles are positioned to benefit from the low-inflation environment. Sonthalia also highlights opportunities in the pharmaceutical CDMO space, while cautioning about elevated valuations in capital-intensive sectors. He emphasizes the importance of bottom-up stock selection in the current market environment.

*this image is generated using AI for illustrative purposes only.
Market participants are increasingly debating whether equities can regain leadership in the coming financial year, following a period marked by sharp cross-asset movements and persistent investor interest in precious metals. With focus shifting between gold, silver, and stocks, investors are questioning whether a multi-asset approach will continue or if equities are positioned for stronger performance ahead.
Positive FY27 Outlook Driven by Improving Macros
Manish Sonthalia from Emkay Investment Managers believes the outlook for Indian markets is improving meaningfully, with FY27 expected to mark a clear step up from the previous year. "FY27 should be better than FY26 for sure on the back of better macros as far as India is concerned," he stated, highlighting several supportive factors.
Sonthalia expects FY27 to outperform FY26 with 12-13% earnings growth, driven by low inflation, reduced rates, and improving macros. He sees opportunities in rate-sensitive sectors and the pharmaceutical CDMO space.
| Key Macro Factors | Status |
|---|---|
| Inflation | Very low levels |
| Interest Rates | Very low levels |
| Earnings Growth | Reviving trend |
| Valuations | Corrected from previous highs |
The broader setup appears supportive, though markets are awaiting a key global trigger. Sonthalia noted that "market is waiting with bated breath as to see the light of the day for the US trade deal," suggesting that markets may wait until March for clarity on this potential catalyst.
Earnings Growth and Sectoral Outlook
Sonthalia expects earnings growth to regain momentum, projecting FY27 growth at 12-13% with potential upside of around 15% by year-end. His sectoral outlook highlights a mix of financials, industrials, and defensives as key contributors.
Strong Performance Expected
- Banks: Decent earnings growth anticipated
- IT: Projected growth of 6-7%
- Capital goods: Positive outlook
- NBFCs: Expected to perform well
- Healthcare: Strong performance ahead
Sectors Facing Headwinds
- Metals: High base effect concerns
- Oil and Gas: Challenging comparisons
Rate-Sensitive Sectors Positioned to Benefit
In the low-inflation environment, rate-sensitive segments could emerge as significant beneficiaries. Sonthalia highlighted several areas poised for growth:
| Sector | Growth Drivers |
|---|---|
| Real Estate | Rate cuts and policy support |
| Automobiles | Lower rates and rising freight costs |
| Auto Components | Supportive rate environment |
| Discretionary Consumption | Premium segment outperforming staples |
Consumption-linked segments could benefit from multiple policy tailwinds, including "rate cuts, GST cuts, income tax cuts, and one lakh crore incentive," all contributing to consumption growth.
Valuation Concerns in Capital-Intensive Sectors
Despite growth visibility in infrastructure-related areas, Sonthalia continues to flag valuation concerns in capital-intensive sectors. "Valuations are still very elevated because some of these favoured sectors are discounting probably FY28-29 and no room for error," he cautioned.
While growth visibility exists in roads, railways, defense, and capital goods, much of the expected performance appears already priced in, potentially limiting near-term returns.
Pharmaceutical Sector Opportunities
Sonthalia remains constructive on pharmaceuticals, particularly if generics remain outside tariff discussions. He sees significant promise in the CDMO (Contract Development and Manufacturing Organization) segment, which has undergone sharp correction.
| CDMO Opportunities | Details |
|---|---|
| Market Size | Minuscule compared to global market |
| Growth Potential | Massive opportunity from China shift |
| Patent Expiry | GLP-1 going off patent from April 26 |
| Supply Chain | Benefiting from global shifts |
"One space which has seen significant correction is basically the CDMO space... this is one space which is very-very exciting," Sonthalia emphasized, highlighting structural opportunities from global supply chain shifts.
Investment Strategy and Stock Selection
As leadership within sectors shifts, Sonthalia underscored the growing importance of bottom-up stock selection. He stressed that "you cannot paint everything with the same brush saying that everything is very expensive and the mid and smallcap universe is to be avoided totally."
The investment manager believes valuations have corrected meaningfully in pockets, creating selective opportunities for investors who focus on individual stock fundamentals rather than broad market generalizations.
Overall, Sonthalia believes FY27 could reward disciplined investors who focus on valuations, sectoral tailwinds, and bottom-up stock selection rather than chasing crowded investment themes.
































